Posted by Michael Wonder on 29 May 2023
Ultomiris approved in Japan for the prevention of relapses in patients with neuromyelitis optica spectrum disorder
26 May 2023 - Ultomiris has the potential to eliminate relapses and redefine the treatment landscape for anti-aquaporin-4 (AQP4) antibody positive neuromyelitis optica spectrum disorder.
Ultomiris (ravulizumab) has been approved in Japan as the first and only long-acting C5 complement inhibitor for the prevention of relapses in patients with anti-aquaporin-4 antibody positive neuromyelitis optica spectrum disorder, including neuromyelitis optica.
